A phase I and pharmacokinetic study of daily oral cediranib, an inhibitor of vascular endothelial growth factor tyrosine kinases, in combination with cisplatin and gemcitabine in patients with advanced non-small cell lung cancer: A study of the National Cancer Institute of Canada Clinical Trials Group

European Journal of Cancer

Volumn 45, Issue 5, 2009, Pages 782-788

  Goss, Glenwood ^a   Shepherd, Frances A ^b   Laurie, Scott ^a   Gauthier, Isabelle ^a   Leighl, N ^b   Chen, Eric ^b   Feld, Ronald ^b   Powers, Jean ^c   Seymour, Lesley ^c  

^a OTTAWA REGIONAL CANCER CENTRE   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

^c QUEEN S UNIVERSITY   (Canada)

Author keywords

Cebiranib; Chemotheraphy; Non small cell lung cancer; Phase I

Indexed keywords

CEDIRANIB; CISPLATIN; GEMCITABINE; PROTEIN TYROSINE KINASE INHIBITOR; VASCULOTROPIN INHIBITOR;

ADULT; ADVANCED CANCER; AGED; ANOREXIA; ANTINEOPLASTIC ACTIVITY; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BLEEDING; BLOOD TOXICITY; BONE MARROW SUPPRESSION; BRAIN INFARCTION; CANADA; CANCER COMBINATION CHEMOTHERAPY; CANCER RADIOTHERAPY; CLINICAL ARTICLE; CLINICAL TRIAL; CONFUSION; CONSTIPATION; CREATININE BLOOD LEVEL; DEHYDRATION; DIARRHEA; DISTRIBUTION VOLUME; DIZZINESS; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DOSE ESCALATION; DRUG DOSE REDUCTION; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG ELIMINATION; DRUG POTENCY; DRUG SCREENING; DRUG TOLERABILITY; DRUG WITHDRAWAL; DRY SKIN; EPISTAXIS; FATIGUE; FEMALE; GASTRITIS; GASTROINTESTINAL SYMPTOM; GRANULOCYTOPENIA; HAND FOOT SYNDROME; HEADACHE; HEARTBURN; HEMOPTYSIS; HOARSENESS; HUMAN; HYPERTENSION; HYPOTENSION; LIMB WEAKNESS; LUNG NON SMALL CELL CANCER; MALE; MONOTHERAPY; MOOD DISORDER; MUCOSA INFLAMMATION; MULTIPLE CYCLE TREATMENT; NAUSEA; NEPHROTOXICITY; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; PROTEINURIA; RASH; SENSORY NEUROPATHY; SIDE EFFECT; SUPERIOR CAVA VEIN OBSTRUCTION; THROMBOCYTOPENIA; THROMBOSIS; TREATMENT OUTCOME; VOICE CHANGE; VOMITING; WEAKNESS;

ADMINISTRATION, ORAL; ADULT; AGED; ANGIOGENESIS INHIBITORS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, NON-SMALL-CELL LUNG; CISPLATIN; DEOXYCYTIDINE; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; FEMALE; HEMATOLOGIC DISEASES; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM STAGING; QUINAZOLINES; TREATMENT OUTCOME;

EID: 61349124193     PISSN: 09598049     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejca.2008.10.022     Document Type: Article

References (28)

1. Canadian cancer statistics 2007. Toronto, Canada: National Cancer Institute of Canada; April, 2007.
2. Jemal A., Siegel R., Ward E., et al. Cancer statistics 2008. CA Cancer J Clin 58 (2008) 71-96
3. Schiller J.H., Harrington D., Belani C.P., et al. Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. N Engl J Med 346 (2002) 92-98
4. Shepherd F.A., Dancey J., Ramlau R., et al. Prospective randomized trial of docetaxel versus best supportive care in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy. J Clin Oncol 18 (2000) 2095-2103
5. Shepherd F.A., Pereira J.R., Ciuleanu T., et al. Erlotinib in previously treated non-small-cell lung cancer. N Engl J Med 353 (2005) 123-132
6. Ferrara N., Gerber H.P., and LeCouter J. The biology of VEGF and its receptors. Nat Med 9 (2003) 669-676
7. Bremnes R.M., Camps C., and Sirera R. Angiogenesis in non-small cell lung cancer: the prognostic impact of neoangiogenesis and the cytokines VEGF and bFGF in tumours and blood. Lung Cancer 51 (2006) 143-158
8. Sandler A., Gray R., Perry M.C., et al. Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med 355 (2006) 2542-2550
9. Johnson D.H., Fehrenbacher L., Novotny W.F., et al. Randomized phase II trial comparing bevacizumab plus carboplatin and paclitaxel with carboplatin and paclitaxel alone in previously untreated locally advanced or metastatic non-small-cell lung cancer. J Clin Oncol 22 (2004) 2184-2191
10. Wedge S.R., Kendrew J., Hennequin L.F., et al. AZD2171: a highly potent, orally bioavailable, vascular endothelial growth factor receptor-2 tyrosine kinase inhibitor for the treatment of cancer. Cancer Res 65 (2005) 4389-4400
11. Drevs J., Medinger M., Mross K., et al. Phase I clinical evaluation of AZD2171, a highly potent VEGF receptor tyrosine kinase inhibitor, in patients with advanced tumors. J Clin Oncol 23 16S (2005) [part 1 of 3]
12. Laurie S.A., Gauthier I., Arnold A., et al. Phase I and pharmacokinetic study of daily oral AZD2171, an inhibitor of vascular endothelial growth factor tyrosine kinases, in combination with carboplatin and paclitaxel in patients with advanced non-small-cell lung cancer: The National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 26 (2008) 1871-1878
13. Therasse P., Arbuck S.G., Eisenhauer E.A., et al. New guidelines to evaluate the response to treatment in solid tumors. J Nat Cancer Inst 92 (2000) 205-216
14. Gauthier I, Laurie SA, Arnold A, et al. Hypertension: experience in IND.171, a phase I dose seeking trial combining AZD2171 with standard chemotherapy in patients with advanced incurable non-small cell lung cancer (NSCLC). Poster presentation at the 8th international symposium on angiogenesis, San Diego, February 3-5, 2006.
15. Willey T.A., Bekos E.J., Gaver R.C., et al. High-performance liquid chromatographic procedure for the quantitative determination of paclitaxel (Taxol) in human plasma. J Chromatogr 24 (1993) 231-238
16. Zufia L., Aldaz A., Castellanos C., et al. Simple and rapid determination of carboplatin in plasma by high-performance liquid chromatography. Error pattern and application to clinical pharmacokinetic studies. J Chromatogr B Biomed Sci Appl 25 (2001) 457-464
17. Escudier B., Eisen T., Stadler W.M., et al. Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med 356 (2007) 125-134
18. Motzer R.J., Hutson T.E., Tomczak P., et al. Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med 356 (2007) 115-124
19. Hurwitz H., Fehrenbacher L., Novotny W.F., et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 350 (2004) 2335-2342
20. Jain R.K. Normalizing tumor vasculature with anti-angiogenic therapy: a new paradigm for combination therapy. Nat Med 7 (2001) 987-989
21. Willett C.G., Boucher Y., di Tomaso E., et al. Direct evidence that the VEGF-specific antibody bevacizumab has antivascular effects in human rectal cancer. Nat Med 10 (2004) 145-147
22. Batchelor T.T., Sorensen A.G., di Tomaso E., et al. AZD2171, a pan-VEGF receptor tyrosine kinase inhibitor, normalizes tumor vasculature and alleviates edema in glioblastoma patients. Cancer Cell 11 (2007) 83-95
23. Alberts SR, Morlan BW, Kim GP, et al. NCCTG phase II trial (N044J) of AZD2171 for patients with hepatocellular carcinoma (HCC) - interim review of toxicity. NCCTG spring meeting; 2007.
24. Sridhar S., Hotte S., MacKenzie M.J., et al. Phase II study of the angiogenesis inhibitor AZD2171 in first-line progressive unresectable, advanced metastatic renal cell carcinoma (RCC): a trial of the PMH phase II consortium. J Clin Oncol 25 18S (2007) 5093
25. Ryan C.J., Stadler W.M., Roth B., et al. Phase I dose escalation and pharmacokinetic study of AZD2171, an inhibitor of the vascular endothelial growth factor receptor tyrosine kinase, in patients with hormone refractory prostate cancer (HRPC). Invest New Drugs 25 5 (2007) 445-451
26. Van Cruijsen H., Voest E.E., Van Herpen C.M., et al. Phase I evaluation of AZD2171, a highly potent, selective VEGFR signaling inhibitor, in combination with gefitinib, in patients with advanced tumors. J Clin Oncol 24 18S (2006) 3560
27. Shields A., Heath E., DeLuca P., et al. AZD2171 in combination with various anticancer regimens: follow-up results of a phase I multi-cohort study. J Clin Oncol 25 18S (2007) 3544
28. Chen E., Jonker D., Gauthier I., et al. Phase I study of daily oral AZD2171, an inhibitor of the vascular endothelial growth factor receptors, in combination with oxaliplatin and infusional 5FU (mFOLFOX6) in patients with advanced colorectal cancer: a study of The National Cancer Institute of Canada Clinical Trials Group. Eur J Can Suppl 4 12 (2006) 32